Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-01

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gluteus medius tendinopathy, which is often referred to as Greater Trochanteric Pain Syndrome, is characterized by pain in the lateral aspect of the hip that is aggravated by side lying, stair climbing, and walking. Treatment is currently limited to lifestyle modifications, corticosteroid injections, physical therapy, and open and endoscopic surgical repair. Platelet rich plasma (PRP) injections contain important growth factors that are essential in the healing and tissue formation processes. However, the extent to which PRP is more efficacious than whole blood in tendinopathy remains unclear. In this double-blind randomized trial, patients will be allocated to receive either a PRP or whole-blood injection. Post-procedure assessments will occur at 6 weeks, 3 months, 6 months, 9 months, and 1 year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Knee Arthropathy

NCT06261632

Hemophilia

ACTIVE_NOT_RECRUITING NA

The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial

NCT00761423

Achilles Tendinopathy

COMPLETED PHASE4

Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement

NCT00161902

Hip Replacement Surgery

COMPLETED PHASE3

Outcomes of Femoro-popliteal Disease After Stent Deployment Under Intravascular Ultrasound Guidance

NCT02037113

Peripheral Arterial Disease

TERMINATED

Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System

NCT02097082

Peripheral Arterial Disease Intermittent Claudication Vascular Diseases +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tendinopathy Hip Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP

Group Type EXPERIMENTAL

PRP

Intervention Type BIOLOGICAL

Ultrasound

Intervention Type DEVICE

Whole Blood

Group Type ACTIVE_COMPARATOR

Whole Blood

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP

Intervention Type BIOLOGICAL

Whole Blood

Intervention Type BIOLOGICAL

Ultrasound

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe lateral hip pain for greater than 3 months
* Symptoms are refractory to conservative treatment, including at least 8 weeks of traditional physical therapy for this condition
* Moderate to severe gluteus medius tendinosis with or without partial tear \<1 cm
* Normal neurologic exam except for hip abductor weakness on the affected side

Exclusion Criteria

* Severe (Tonnis grade \>1) hip osteoarthritis with active synovitis or bone edema
* Active lumbar radiculopathy with pain, numbness or weakness in a dermatomal distribution
* No evidence of fatty atrophy, denervation, or complete tears of gluteus medius seen on MRI
* Any condition that requires anti-platelet or anti-coagulation therapy, including aspirin therapy for cardiac conditions
* Non-English speaking

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No